DAP-kinase and HOXA9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer

• US 20030224509A1
• Filed: 11/29/2001
• Published: 12/04/2003
• Est. Priority Date: 11/29/2000
• Status: Abandoned Application

• Current Assignee: Cangen Biotechnologies Incorporated
• Original Assignee: Cangen International
• Inventors: Moon, Chulso, Mao, Li
• Application Number:
  US10/045,400
• Publication Number:
  US 20030224509A1
• Time in Patent Office: Days
• US Class Current: 435/325
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C12N 9/12 transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The invention relates to the discovery of two markers that are informative for one or more of tumorigenesis, tumor progression, and tumor aggressiveness associated with non-small cell lung cancer (NSCLC). The markers are the HOXA9 gene and the gene encoding death-associated protein kinase (DAP-kinase) of humans. Methods of diagnosing NSCLC and methods of assessing the degree of progression and aggressiveness of NSCLC tumors are disclosed, as are methods of inhibiting or alleviating NSCLC. The invention also includes screening methods for identifying compounds that are useful for alleviating, inhibiting, or preventing NSCLC.

Claims

1. A method of diagnosing non-small cell lung cancer (NSCLC) in a human, the method comprising assessing expression of the gene encoding DAP-kinase in lung cells of the human, whereby a lower degree of expression of the gene in the human, relative to a normal level of expression of the gene in humans not afflicted with NSCLC, is an indication that the human is afflicted with NSCLC.

2. The method of claim 1, wherein expression of the gene is assessed in vitro in cells obtained from the human.

3. The method of claim 2, wherein the cells are obtained from a bronchial lavage.

4. The method of claim 2, wherein the cells are epithelial cells.

5. The method of claim 1, wherein the human does not exhibit a macroscopic clinical symptom of NSCLC.

6. The method of claim 5, wherein the symptom is selected from the group consisting of a cough that doesn'"'"'t go away and gets worse over time, constant chest pain, coughing up blood, shortness of breath, wheezing, hoarseness, repeated problems with pneumonia, repeated problems with bronchitis, swelling of the neck and face, loss of appetite, weight loss, and fatigue.

7. The method of claim 1, wherein expression of the gene is assessed by assessing the methylation state of the gene.

8. The method of claim 7, wherein the methylation state of the gene is assessed by assessing the methylation state of the promoter CpG region of the gene.

9. The method of claim 7, wherein the methylation state of the gene is assessed using an oligonucleotide that specifically hybridizes with the methylated form of the gene.

10. The method of claim 9, wherein the oligonucleotide and a second oligonucleotide are used in a polymerase chain reaction (PCR) to amplify a portion of the gene.

11. A method of assessing NSCLC tumorigenesis at an early stage in a human, the method comprising assessing methylation of the gene encoding DAP-kinase in lung cells of the human.

12. A method of assessing aggressiveness of a NSCLC tumor in a human, the method comprising assessing methylation of the gene encoding DAP-kinase in lung cells of the human, whereby a higher degree of methylation of the gene is an indication that the tumor is more aggressive.

13. The method of claim 12, wherein the tumor is a diagnostic stage I NSCLC tumor.

14. A method of selecting among methods of treating a NSCLC tumor in a human, the method comprising assessing methylation of the gene encoding DAP-kinase in lung cells of the human and selecting a more aggressive treatment when a higher degree of methylation of the gene is detected.

15. A method of inhibiting NSCLC tumorigenesis in a human, the method comprising inhibiting methylation of the DAP-kinase gene in lung cells of the human.

16. A method of inhibiting progression of a NSCLC tumor in a human, the method comprising inhibiting methylation of the DAP-kinase gene in cells of the tumor.

17. A method of reducing the aggressiveness of a NSCLC tumor in a human, the method comprising inhibiting methylation of the DAP-kinase gene in cells of the tumor.

18. A method of inhibiting NSCLC tumorigenesis in a human, the method comprising de-methylating the DAP-kinase gene in lung cells of the human.

19. A method of inhibiting progression of a NSCLC tumor in a human, the method comprising de-methylating the DAP-kinase gene in cells of the tumor.

20. A method of reducing the aggressiveness of a NSCLC tumor in a human, the method comprising de-methylating the DAP-kinase gene in cells of the tumor.

21. A method of assessing the risk that a human will develop NSCLC, the method comprising assessing expression of the gene encoding DAP-kinase in lung cells of the human, whereby a lower degree of expression of the gene in the human, relative to a normal level of expression of the gene in humans not afflicted with NSCLC, is an indication that the human is at an increased risk for developing NSCLC.

22. A method of assessing whether a test compound is useful for inhibiting a process selected from the group consisting of i) NSCLC tumorigenesis, ii) progression of a NSCLC tumor, and iii) aggressiveness of a NSCLC tumor, the method comprising comparing methylation of the DAP-kinase gene in the presence of the test compound and methylation of the gene in the absence of the test compound, whereby a lower degree of gene methylation in the presence of the test compound is an indication that the test compound is useful for inhibiting the process.

23. A method of preventing NSCLC in a human at risk for developing NSCLC, the method comprising inhibiting methylation of the DAP-kinase gene in lung cells of the human.

24. A method of preventing NSCLC in a human at risk for developing NSCLC, the method comprising enhancing de-methylation of the DAP-kinase gene in lung cells of the human.

25. A method of alleviating NSCLC in a human, the method comprising inhibiting methylation of the DAP-kinase gene in lung cells of the human.

26. A method of alleviating NSCLC in a human, the method comprising enhancing de-methylation of the DAP-kinase gene in lung cells of the human.

27. A method of diagnosing NSCLC in a human, the method comprising assessing expression of the HOXA9 gene in lung cells of the human, whereby a greater degree of expression of the gene in the human, relative to a normal level of expression of the gene in humans not afflicted with NSCLC, is an indication that the human is afflicted with NSCLC.

28. The method of claim 27, wherein expression of the gene is assessed in vitro in cells obtained from the human.

29. The method of claim 28, wherein the cells are obtained from a bronchial lavage.

30. The method of claim 28, wherein the cells are epithelial cells.

31. The method of claim 27, wherein the human does not exhibit a macroscopic clinical symptom of NSCLC.

32. The method of claim 31, wherein the symptom is selected from the group consisting of a cough that doesn'"'"'t go away and gets worse over time, constant chest pain, coughing up blood, shortness of breath, wheezing, hoarseness, repeated problems with pneumonia, repeated problems with bronchitis, swelling of the neck and face, loss of appetite, weight loss, and fatigue.

33. The method of claim 27, wherein expression of the gene is assessed using an oligonucleotide that specifically hybridizes with a transcription product of the gene.

34. The method of claim 33, wherein the oligonucleotide does not specifically hybridize with the gene.

35. The method of claim 33, wherein the oligonucleotide and a second oligonucleotide are used in a polymerase chain reaction (PCR) to amplify a portion of the gene.

36. The method of claim 35, wherein the portion includes sub-portions wherein an intron is interposed between the sub-portions in the gene, but wherein the sub-portions are adjacent in mRNA derived from the gene.

37. A method of assessing the risk that a human will develop NSCLC, the method comprising assessing expression of the HOXA9 gene in lung cells of the human, whereby a greater degree of expression of the gene in the human, relative to a normal level of expression of the gene in humans not afflicted with NSCLC, is an indication that the human is at an increased risk for developing NSCLC.

38. A method of inhibiting NSCLC tumorigenesis in a human, the method comprising inhibiting expression of the HOXA9 gene in lung cells of the human.

39. A method of inhibiting progression of a NSCLC tumor in a human, the method comprising inhibiting expression of the HOXA9 gene in cells of the tumor.

40. A method of assessing whether a test compound is useful for inhibiting a process selected from the group consisting of i) NSCLC tumorigenesis and ii) progression of a NSCLC tumor, the method comprising comparing expression of the HOXA9 gene in the presence of the test compound and expression of the gene in the absence of the test compound, whereby a lower degree of expression in the presence of the test compound is an indication that the test compound is useful for inhibiting the process.

41. A method of preventing NSCLC in a human at risk for developing NSCLC, the method comprising inhibiting expression of the HOXA9 gene in lung cells of the human.

42. A method of alleviating NSCLC in a human, the method comprising inhibiting expression of the HOXA9 gene in lung cells of the human.